GlassScriptPhysician profile
Patrick Joseph Renton
NPI 1841409877
$842.05
in general payments reported to CMS, 2019-2025
15 companies · $124 in 2025
The $124 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $37.44 · 2021: $32.25 · 2022: $97.87 · 2023: $87.60 · 2024: $186 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $277.68 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Sanofi Pasteur INC. | $82.14 | 2019-2025 | |
| Pfizer INC. | $78.54 | 2020-2025 | |
| Glaxosmithkline, LLC. | $74.16 | 2019-2024 | Bexsero, Pediarix |
| Supernus Pharmaceuticals, INC. | $65.34 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $63.58 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $40.27 | 2022 | |
| Neos Therapeutics, LP | $38.01 | 2019-2024 | Adzenys Xr-Odt |
| Corium, LLC | $23.54 | 2024 | Azstarys |
| Seqirus USA INC | $21.37 | 2023 | Flucelvax Quadrivalent |
| Verrica Pharmaceuticals INC. | $18.11 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $17.87 | 2023 | Flumist Quadrivalent |
| Shire North American Group INC | $14.40 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.69 | 2019 | |
| Cranial Technologies, INC | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Renton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.